HTG Molecular Diagnostics Transfers Listing to The Nasdaq Capital Market
18 April 2017 - 6:01AM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of
instruments, reagents and services for molecular profiling
applications, announced that, on April 12, 2017, the
company received formal notice from The NASDAQ Stock Market LLC
indicating that the Nasdaq Hearings Panel had granted the Company's
request to transfer the listing of HTG’s common stock from The
Nasdaq Global Market to The Nasdaq Capital Market based upon HTG’s
compliance with all requirements for continued listing on the
latter market. The intra-market transfer took effect upon the open
of trading this morning, Monday, April 17, 2017.
“We are pleased to have this listing compliance matter behind
us, and continue our focus on building long-term shareholder
value,” stated TJ Johnson, President and Chief Executive Officer of
HTG.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular
Diagnostics (HTG) is to empower precision medicine at the local
level. In 2013 the company commercialized its first instrument
platform and a portfolio of RNA assays that leveraged HTG's
original proprietary nuclease protection chemistry. Continuous
improvement led to the 2014 launch of the company’s HTG EdgeSeq
product line, which automates sample and targeted library
preparation for next-generation sequencing. Additional information
is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the expected timing for the
transfer of our common stock to The Nasdaq Capital Market. Words
such as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based upon management's current
expectations, are subject to known and unknown risks, and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties,
including, without limitation, risks described in our our Annual
Report on Form 10-K for the year ended December 31, 2016. All
forward-looking statements contained in this press release speak
only as of the date on which they were made, and we undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2024 to May 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From May 2023 to May 2024